Free tool
Stocks listed on Nasdaq CM
We cover 18 companies listed on Nasdaq CM. The median market value in the group is $3.26B. Across the group, the median move over the past trading day is −0.71%. Price change over the past year runs from +30.2% to +260.8% across the middle 80 percent of the group, with a median of +118.3%.
Other lists in this group
Table
18 of 1,344 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| CORT | Corcept Therapeutics Incorporated | $12.95B | Large cap | +71.81% |
| TGTX | TG Therapeutics, Inc. Common Stock | $8.42B | Mid cap | +92.61% |
| BLTE | Belite Bio, Inc | $6.31B | Mid cap | +144.07% |
| LQDA | Liquidia Corporation | $6.31B | Mid cap | +154.86% |
| DNTH | Dianthus Therapeutics, Inc. | $6.13B | Mid cap | +356.93% |
| CELC | Celcuity Inc. | $4.65B | Mid cap | +90.31% |
| VKTX | Viking Therapeutics, Inc. | $4.01B | Mid cap | +29.15% |
| PLSE | Pulse Biosciences, Inc. | $3.43B | Mid cap | +203.47% |
| IMNM | Immunome, Inc. | $3.34B | Mid cap | +188.94% |
| CLDX | Celldex Therapeutics, Inc. | $3.19B | Mid cap | +79.51% |
| SLS | SELLAS Life Sciences Group, Inc. | $2.77B | Mid cap | +615.10% |
| VRDN | Viridian Therapeutics, Inc. | $2.75B | Mid cap | +30.71% |
| RGC | Regencell Bioscience Holdings Limited | $2.72B | Mid cap | −61.38% |
| AXGN | AxoGen, Inc. Common Stock | $2.68B | Mid cap | +219.58% |
| NKTR | Nektar Therapeutics | $2.52B | Mid cap | +151.95% |
| UFPT | UFP Technologies, Inc. | $2.36B | Mid cap | +41.94% |
| NEO | NeoGenomics, Inc. | $2.26B | Mid cap | +145.34% |
| ESTA | Establishment Labs Holdings Inc. | $2.15B | Mid cap | +70.71% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.